Cargando…
A 12-week Comparative Prospective Open-label Randomized Controlled Study in Depression Patients Treated with Vilazodone and Escitalopram in a Tertiary Care Hospital in North India
BACKGROUND: Depression is a leading cause of morbidity in modern world and introduction of selective serotonin reuptake inhibitors (SSRIs) was a revolution for treating depression. However, sexual dysfunction and weight gain always remained an issue for patients leading to discontinuation of treatme...
Autores principales: | Bathla, Manish, Anjum, Shazia, Singh, Manpreet, Panchal, Saminder, Singh, Gurvinder Pal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795684/ https://www.ncbi.nlm.nih.gov/pubmed/29403135 http://dx.doi.org/10.4103/IJPSYM.IJPSYM_368_17 |
Ejemplares similares
-
A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression
por: Bathla, Manish, et al.
Publicado: (2020) -
An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus
Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022) -
An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023) -
Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study
por: Kadam, Renuka L., et al.
Publicado: (2020) -
Assessment of quality of sleep and its association with body mass index among medical consultants working in a medical college in northern India
por: Bathla, Manish, et al.
Publicado: (2020)